Vickers Venture Fund VI

Vickers Venture Partners is a global venture capital firm headquartered in Singapore that specializes in early-stage "deep tech" investments. Its sixth flagship fund, Vickers Venture Fund VI, focuses significantly on the life sciences, biotechnology, and healthcare sectors, alongside artificial intelligence and nanotechnology. The firm is known for its contrarian investment strategy, backing disruptive technologies with the potential for global impact. Key healthcare-related portfolio companies within Fund VI include Biosplice Therapeutics, which focuses on regenerative medicine, and Emergex Vaccines, which develops synthetic T-cell vaccines. Additionally, the fund has invested in SiSaf, a company advancing RNA delivery technologies for rare genetic disorders. Vickers Venture Partners operates globally with offices in major innovation hubs including New York, San Diego, and London.